Traditional Chinese medicine fumigation composition for treating meibomian gland dysfunction and preparation method thereof

Abstract

The invention provides a traditional Chinese medicine fumigation composition for treating meibomian gland dysfunction, and relates to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 20 parts of poria cocos, 5 to 10 parts of exocarpium citri rubrum, 10 to 15 parts of radix scutellariae, 10 to 15 parts of flos buddlejae and 5 to 10 parts of liquorice root. The preparation method comprises the following steps: S1, respectively crushing the raw materials, uniformly mixing, and sub-packaging into medicine bags; s2, the medicine bag is placed in a container, water is added for decoction, and traditional Chinese medicine liquid, namely the fumigation composition, is obtained. The tuckahoe is used as a monarch drug, the scutellaria baicalensis and the butterflybush flower are used as ministerial drugs, the tangerine is used as an adjuvant drug, and the liquorice is used as a conductant drug, so that the traditional Chinese medicine has the effects of clearing heat, removing opacity and eliminating dampness and heat.

Description

Technical Field

[0001] The invention relates to the field of traditional Chinese medicine, and in particular to a traditional Chinese medicine fumigation composition for treating meibomian gland dysfunction. Background Art

[0002] Meibomian gland dysfunction (MGD) is a chronic ocular surface disease that is relatively common in clinical practice. Its main characteristics are abnormal lipid secretion from the meibomian glands and obstruction of the terminal ducts of the meibomian glands. It can cause eye irritation, lead to unstable tear film, and ultimately induce dry eye syndrome, affecting the patient's vision and reducing the patient's quality of life.

[0003] TCM describes meibomian gland dysfunction as: all diseases originate from within, and must manifest externally. The upper and lower eyelids are related to the spleen internally, and the spleen governs muscles, so they are called meat wheels. Meat wheels occur externally, which must be related to the imbalance of the spleen, stomach and five internal organs, or spleen and stomach heat accumulation, phlegm and heat, fatty and sweet food, endogenous phlegm and dampness, which in turn leads to the phlegm heat and qi and blood in the eyelids; or spleen and stomach dysfunction, qi and blood stagnation, and phlegm and dampness endogenous, which hinders the eyelids. Therefore, TCM treatment of patients with meibomian gland dysfunction advocates detoxification, antipyretic, wind and dampness dispersing.

[0004] Anti-inflammatory, local massage, and hot compress measures are currently the commonly used means of clinical treatment of meibomian gland dysfunction. Although the effect is acceptable, it is very easy to relapse, and the long-term effect is not ideal. Nowadays, physical therapy has become an effective method for clinical treatment of patients with meibomian gland dysfunction. Summary of the invention

[0005] The invention aims to provide a traditional Chinese medicine fumigation composition for treating meibomian gland dysfunction, which uses Poria as a main drug, Scutellaria baicalensis and Buddleja buddleja as assistant drugs, Citrus aurantium as an adjuvant drug, and Licorice as a guiding drug, and has the effects of clearing away heat, removing red cataracts, and promoting dampness and heat.

[0006] Another object of the present invention is to provide a method for preparing a traditional Chinese medicine fumigation composition for treating meibomian gland dysfunction, wherein the preparation method is simple.

[0007] The present invention solves the technical problem by adopting the following technical solutions.

[0008] On the one hand, an embodiment of the present invention provides a traditional Chinese medicine fumigation composition for treating meibomian gland dysfunction, comprising the following raw materials by weight:

[0009] 10-20 parts of Poria cocos, 5-10 parts of Citrus aurantium, 10-15 parts of Scutellaria baicalensis, 10-15 parts of Buddleja buddleja, and 5-10 parts of Licorice.

[0010] In some embodiments of the present invention, the following raw materials are included by weight:

[0011] 10 parts of Poria, 10 parts of Orange Peel, 10 parts of Scutellaria baicalensis, 10 parts of Buddleja Buddleja, and 10 parts of Licorice.

[0012] In some embodiments of the present invention, the following raw materials are included by weight:

[0013] 20 parts of Poria cocos, 5 parts of Citrus aurantium, 15 parts of Scutellaria baicalensis, 15 parts of Buddleja mongholicus, and 5 parts of Licorice.

[0014] In some embodiments of the present invention, the following raw materials are included by weight:

[0015] 15 parts of Poria, 8 parts of Orange Peel, 12 parts of Scutellaria baicalensis, 12 parts of Buddleja Buddleja, and 12 parts of Licorice.

[0016] On the other hand, an embodiment of the present invention provides a method for preparing a traditional Chinese medicine fumigation composition for treating meibomian gland dysfunction, comprising the following steps:

[0017] S1: Grind the raw materials separately, mix them evenly, and pack them into medicine bags;

[0018] S2: placing the medicine bag in a container, adding water and boiling to obtain a Chinese medicine liquid, which is the fumigation composition.

[0019] In some embodiments of the present invention, in step S1, the particle size of each raw material after crushing is 40-100 mesh.

[0020] In some embodiments of the present invention, in step S1, the particle size of each raw material after crushing is 50 mesh.

[0021] In some embodiments of the present invention, in step S2, the boiling time is 10-20 minutes.

[0022] Compared with the prior art, the embodiments of the present invention have at least the following advantages or beneficial effects:

[0023] The fumigation composition provided by the present invention comprises a main drug, Poria cocos, which is good at removing dampness and has good effects on cold and dampness, damp heat, internal heat, etc., and a ministerial drug, Scutellaria baicalensis and Buddleja buddlejae, which can regulate the yin and yang balance of the human body, remove damp heat in the lungs, liver and gallbladder, and large and small intestines, and can better improve the skin sores and swelling caused by damp heat stagnation. Buddleja buddlejae has the effects of clearing heat and nourishing the liver, improving eyesight and removing cataracts, and has a good effect on treating photophobia and tearing, red and swollen eyes, and the two are combined with the main drug, and are supplemented with the effects of clearing heat, removing red cataracts, and removing damp heat. The adjuvant is Citrus aurantium, which has the function of drying dampness and resolving phlegm, and assists the main and ministerial drugs. The adjuvant is Licorice root, which is flat in nature and harmonizes the Chu drug.

[0024] The raw materials are crushed and made into medicine bags. By adding water and boiling, the effective ingredients in the Chinese medicinal materials are dissolved in the water, and then the medicine is used for fumigation on the eyes, so that the heat and medicine can act on the patient's eyes together to nourish the eyes. The hot air can accelerate the penetration and absorption of the skin, so that the medicine can enter the capillaries and accelerate metabolism; steam can also stimulate the expansion of capillaries, accelerate blood circulation, and improve the vitality and regeneration of cell tissues. Through the Chinese medicine fumigation method, the local temperature is increased, the viscosity of the meibomian gland lipids is reduced, and it is liquefied for easy discharge, so as to achieve the purpose of improving the patient's condition. DETAILED DESCRIPTION

[0025] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0026] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments may be combined with each other. The present invention will be described in detail below with reference to specific embodiments.

[0027] On the one hand, an embodiment of the present invention provides a traditional Chinese medicine fumigation composition for treating meibomian gland dysfunction, comprising the following raw materials by weight:

[0028] 10-20 parts of Poria cocos, 5-10 parts of Citrus aurantium, 10-15 parts of Scutellaria baicalensis, 10-15 parts of Buddleja buddleja, and 5-10 parts of Licorice.

[0029] Preferably, the following raw materials are included by weight: 10 parts of Poria cocos, 10 parts of Citrus aurantium, 10 parts of Scutellaria baicalensis, 10 parts of Buddleja monnieri, and 10 parts of Licorice.

[0030] Preferably, the following raw materials are included by weight: 20 parts of Poria cocos, 5 parts of Citrus aurantium, 15 parts of Scutellaria baicalensis, 15 parts of Buddleja monnieri, and 5 parts of Licorice.

[0031] Preferably, the following raw materials are included by weight: 15 parts of Poria cocos, 8 parts of Citrus aurantium, 12 parts of Scutellaria baicalensis, 12 parts of Buddleja monnieri, and 12 parts of Licorice.

[0032] The Chinese medicinal materials used in this invention all comply with the quality standards of the 2020 edition of the Pharmacopoeia of the People's Republic of China, as follows:

[0033] 1. Poria

[0034] Origin: The dried sclerotium of the Polyporaceae fungus Poria cocos (Schw.) Wolf;

[0035] Characteristics: Blocky, round or irregular, 3-12cm in diameter. Rough surface, gray-brown or reddish-brown. Solid, flat cross section, white or light red, powdery. Odorless, light taste.

[0036] Microscopic characteristics: hyphae are colorless, 2-15 μm in diameter, branched, and septate;

[0037] Quality standards: Water content: not more than 15.0%; Total ash content: not more than 3.0%; Acid-insoluble ash content: not more than 1.0%; Dilute ethanol extract: not less than 3.0%; Efficacy: diuresis, invigorating the spleen and calming the mind;

[0038] 2. Scutellaria baicalensis

[0039] Origin: The dried root of Scutellaria baicalensis Georgi, a plant of the Lamiaceae family;

[0040] Characteristics: The root is cylindrical, slightly curved, 10-20 cm long, 1-2 cm in diameter. The surface is yellow-brown or gray-yellow, with longitudinal wrinkles and long horizontal lenticels;

[0041] Chemical composition: mainly contains flavonoids such as baicalin (≥9.0%), baicalin, and wogonin;

[0042] Quality Standards:

[0043] Moisture: not more than 12.0%; Total ash: not more than 6.0%; Acid insoluble ash: not more than 2.0%; Dilute ethanol extract: not less than 25.0%;

[0044] Pharmacological effects: It has broad-spectrum antibacterial, anti-inflammatory, and antipyretic effects. Modern pharmacological studies have shown that it has a significant inhibitory effect on a variety of bacteria.

[0045] 3. Buddleia flower

[0046] Origin: Dried flower buds of Buddleja officinalis Maxim. of the Loganaceae family.

[0047] Characteristics: The flower buds are long oval, 2-4mm long and 1-2mm in diameter. The surface is gray-green or yellow-green;

[0048] Quality standards: Water content: not more than 12.0%; Total ash content: not more than 9.0%; Acid-insoluble ash: not more than 2.0%; Dilute ethanol extract: not less than 16.0%; Modern pharmacological research: It has anti-inflammatory, liver-protecting, and blood pressure-lowering effects;

[0049] 4. Orange

[0050] Origin: The dried mature peel of the citrus (Citrus reticulata Blanco) and its cultivars of the Rutaceae family;

[0051] Characteristics: Irregular arc-shaped flakes. The outer surface is orange-red or reddish brown, with dense oil chambers;

[0052] Chemical composition: Contains volatile oil (≥1.0%), the main component of which is d-limonene, etc.

[0053] Quality standards: Moisture: not more than 13.0%; Total ash: not more than 6.0%; Dilute ethanol extract: not less than 20.0%;

[0054] Pharmacological effects: It has expectorant, anti-inflammatory and antiasthmatic effects;

[0055] 5. Licorice

[0056] Origin: The dried roots and rhizomes of the leguminous plant licorice (Glycyrrhiza uralensis Fisch.);

[0057] Characteristics: Cylindrical, 30-100cm long, 0.6-3.5cm in diameter. Reddish brown or dark brown on the outside;

[0058] Chemical composition: contains glycyrrhizic acid (≥2.0%), glycyrrhizin, etc.

[0059] Quality standards: Moisture: not more than 10.0%; Total ash: not more than 7.0%; Acid-insoluble ash: not more than 2.0%; Water extract: not less than 20.0%;

[0060] Pharmacological effects: anti-inflammatory, liver-protective, and immunomodulatory effects;

[0061] Quality control of the above medicinal materials:

[0062] 1. All medicinal materials used have been identified to ensure the accuracy of the species;

[0063] 2. Carry out quality inspection in accordance with the 2020 edition of the Pharmacopoeia of the People's Republic of China;

[0064] 3. Storage conditions must be strictly controlled to avoid deterioration;

[0065] 4. Carry out routine inspections such as moisture content and ash content before use;

[0066] 5. Strictly control the content indicators;

[0067] Modern pharmacological studies have shown that the combination of the above-mentioned medicinal materials has a synergistic effect, and the combination has shown good anti-inflammatory and antioxidant pharmacological activities in in vitro experiments.

[0068] The Chinese medicine composition uses Poria as the main drug, which is good at removing dampness and has good effects on cold and dampness, damp heat, internal heat, etc. The ministerial drugs are Scutellaria baicalensis and Buddleja buddlejae. Scutellaria baicalensis can regulate the balance of yin and yang in the human body, remove damp heat in the lungs, liver and gallbladder, and large and small intestines, and can better improve the skin sores and swelling caused by damp heat stagnation. Buddleja buddlejae has the effects of clearing heat and nourishing the liver, improving eyesight and removing cataracts, and has a good effect on treating photophobia and tearing, red and swollen eyes. The two are combined with the main drug, and are supplemented with the effects of clearing heat, removing red cataracts, and removing damp heat. The adjuvant is Citrus aurantium, which has the function of drying dampness and resolving phlegm, and assists the main and ministerial drugs. The messenger drug is Licorice, which is flat in nature and harmonizes the Chu drugs.

[0069] The preparation method of the fumigation Chinese medicine composition comprises the following steps:

[0070] S1: After the raw materials are crushed separately, they are mixed evenly and packaged into medicine bags; the particle size of each raw material after crushing is 40-100 mesh, and preferably, the particle size is 50 mesh. The raw materials are crushed into 40-100 mesh, and the effective ingredients in the raw materials are easily dissolved during the boiling process. Secondly, the particle size is not too small to reduce the production cost. At the same time, the raw materials with small particle size are not easy to filter. The particle size is controlled at 40-100 mesh, which is conducive to the separation of the residue and the liquid medicine after boiling, and there is less precipitation in the Chinese medicine liquid.

[0071] S2: placing the medicine bag in a container, adding water and boiling for 10-20 minutes to obtain a Chinese medicine liquid, which is the fumigation composition.

[0072] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0073] Example 1

[0074] Prepare the Chinese medicinal materials according to the following ratios:

[0075] 10 parts of Poria, 10 parts of Orange Peel, 10 parts of Scutellaria baicalensis, 10 parts of Buddleja Buddleja, and 10 parts of Licorice.

[0076] The Chinese medicine fumigation composition of this embodiment is prepared as follows:

[0077] S1: Grind each raw material into a particle size of 50 mesh, mix them evenly, and pack them into medicine bags;

[0078] S2: placing the medicine bag in a container, adding water and boiling to obtain a Chinese medicine liquid, which is the fumigation composition.

[0079] Example 2

[0080] Prepare the Chinese medicinal materials according to the following ratios:

[0081] 20 parts of Poria cocos, 5 parts of Citrus aurantium, 15 parts of Scutellaria baicalensis, 15 parts of Buddleja mongholicus, and 5 parts of Licorice.

[0082] The Chinese medicine fumigation composition of this embodiment is prepared as follows:

[0083] S1: Grind each raw material into a particle size of 40 mesh, mix them evenly, and pack them into medicine bags;

[0084] S2: placing the medicine bag in a container, adding water and boiling to obtain a Chinese medicine liquid, which is the fumigation composition.

[0085] Example 3

[0086] Prepare the Chinese medicinal materials according to the following ratios:

[0087] 15 parts of Poria, 8 parts of Orange Peel, 12 parts of Scutellaria baicalensis, 12 parts of Buddleja Buddleja, and 12 parts of Licorice.

[0088] The Chinese medicine fumigation composition of this embodiment is prepared as follows:

[0089] S1: Grind each raw material into a particle size of 100 mesh, mix them evenly, and pack them into medicine bags;

[0090] S2: placing the medicine bag in a container, adding water and boiling to obtain a Chinese medicine liquid, which is the fumigation composition.

[0091] Experimental example

[0092] There were 62 samples in this study, with an average age of 46.94, a standard deviation of 16.75, a minimum age of 21, and a maximum age of 78. A total of 18 males were included, accounting for 29.03%, and a total of 44 females were included, accounting for 70.97%. The data showed that there were significantly more female patients than male patients in the study, which is consistent with the epidemiological characteristics that the incidence of dry eye in women is higher than that in men. The age span (21-78 years old) is large, and the average age is in middle age, which is consistent with the age characteristics of dry eye.

[0093] SPSS24 was used for analysis. For categorical data, N (Percent) was used. For quantitative data, if the data met the normal distribution, Mean ± SD was used. If the data did not meet the normal distribution, the non-parametric multi-sample Friedman test was used, and the distribution of the data was expressed in the form of Median (Q1, Q3). For normally distributed data, the independent sample t test was used for comparison between groups, and the paired sample t test was used within the group. For non-normally distributed data, the Mann-Whitney U test was used between groups, and the paired Wilcock signed rank test was used within the group.

[0094] Chi-square test of groups on gender:

[0095] Table 1

[0096]

[0097] The chi-square test was used for analysis, and the corresponding p-value was greater than 0.05, so there was no statistically significant difference between the groups regarding gender.

[0098] Analysis of differences in age among groups:

[0099] Table 2

[0100]

[0101] The independent sample t-test was used for analysis, and the corresponding p-value was greater than 0.05, so there was no statistically significant difference in age between the groups.

[0102] Control group: 20 ml of sterile injection water was injected into the water tank of ultrasonic nebulizer WH-I dry eye nebulizer (manufacturer: Qisheng Medical Instrument Co., Ltd., model: WH-I), and the patient was fitted with the nebulizer eye mask and adjusted for tightness. The patient sat down and the fumigation time was 15 minutes.

[0103] Experimental group: 20 mL of the Chinese medicine solution of Example 1 was injected into the water tank of the ultrasonic nebulizer WH-I dry eye nebulizer (manufacturer: Qisheng Medical Instrument Co., Ltd., model: WH-I). The patient was fitted with the nebulizer eye mask and the tightness was adjusted. The patient sat down and the fumigation time was 15 minutes.

[0104] OSDI score difference analysis:

[0105] OSDI is the Ocular Surface Disease Index, which is used to evaluate the symptoms of ocular surface diseases and their impact on quality of life. The OSDI questionnaire is used, and patients fill in whether they have experienced light sensitivity, foreign body sensation, eye pain, blurred vision, etc. in the past week. The OSDI score calculation formula is: the sum of the above scores × 25 / number of answers, with a full score of 100. The higher the score, the more severe the ocular surface disease. After statistical analysis, the results are shown in Table 3.

[0106] Table 3

[0107]

[0108] The OSDI score data met the normal distribution. The independent sample t test was used for inter-group comparison, and the paired sample t test was used for intra-group comparison. The data in Table 3 showed that:

[0109] 1. Comparison between groups

[0110] Before treatment, there was no significant difference in OSDI scores between the control group and the experimental group (p>0.05), indicating that the baseline levels of the two groups were comparable. In the middle and after treatment, the mean OSDI score of the control group was significantly higher than that of the experimental group (p<0.05), indicating that the treatment effect of the experimental group was better than that of the control group.

[0111] 2. Intra-group comparison

[0112] (1) Control group:

[0113] The value before treatment was significantly greater than that during treatment (t=8.221, p=0.000);

[0114] The value before treatment was significantly greater than that after treatment (t=9.198, p=0.000);

[0115] The value during treatment was significantly greater than that after treatment (t=3.579, p=0.001);

[0116] This indicates that the ocular surface symptoms of patients in the control group improved over time, but the degree of improvement was relatively slow.

[0117] (2) Experimental group:

[0118] The value before treatment was significantly greater than that during treatment (t=20.262, p=0.000);

[0119] The value before treatment was significantly greater than that after treatment (t=31.402, p=0.000);

[0120] The value during treatment was significantly greater than that after treatment (t=8.563, p=0.000);

[0121] This shows that the ocular surface symptoms of patients in the experimental group were significantly improved during the treatment, and the degree of improvement was significantly greater than that in the control group, indicating that the treatment plan of the experimental group had better clinical effect.

[0122] In summary, the statistical analysis results show that:

[0123] 1. The baseline levels of the two groups before treatment were comparable;

[0124] 2. The treatment effect of the experimental group was significantly better than that of the control group;

[0125] 3. The symptoms of both groups of patients improved with the extension of treatment time;

[0126] 4. The improvement in the experimental group was more significant, indicating that this treatment plan has better clinical application value.

[0127] BUT score difference analysis:

[0128] BUT test: Use 1 or 2 drops of saline to wet part of the fluorescein test paper, then gently touch the lower eyelid margin of the subject, and ask the subject to look straight ahead and blink 2 or 3 times under the cobalt blue light of the slit lamp. The time from the last blink to the appearance of a black spot on the corneal surface is the BUT. Repeat 3 times and take the average value. The results are shown in Table 4.

[0129] Table 4

[0130]

[0131] The BUT score data did not meet the normal distribution, so the Mann-Whitney U test was used for inter-group comparison, and the Wilcoxon signed rank test was used for intra-group comparison. The data analysis results showed:

[0132] 1. Comparison between groups

[0133] Before treatment, there was no significant difference in BUT scores between the control group and the experimental group (p>0.05), indicating that the baseline levels of the two groups were comparable. In the middle and after treatment, the BUT score of the experimental group was significantly higher than that of the control group (p<0.05), indicating that the experimental group was more effective in improving tear film stability.

[0134] 2. Intra-group comparison

[0135] (1) Control group:

[0136] The value during treatment was significantly greater than that before treatment (z=-4.802, p=0.000);

[0137] After treatment, it was significantly greater than before treatment (z=-4.814, p=0.000);

[0138] After treatment, it was significantly greater than during treatment (z=-4.205, p=0.000);

[0139] This indicates that the tear film stability of the control group patients improved significantly with the progress of treatment, and the treatment effect showed a continuous upward trend.

[0140] (2) Experimental group:

[0141] The value during treatment was significantly greater than that before treatment (z=-4.946, p=0.000);

[0142] After treatment, it was significantly greater than before treatment (z=-4.970, p=0.000);

[0143] After treatment, it was significantly greater than during treatment (z=-3.753, p=0.000);

[0144] This indicates that the tear film stability of the experimental group of patients was significantly improved during the treatment, and the degree of improvement was more obvious than that of the control group, indicating that the experimental regimen has a better therapeutic effect in improving tear film stability.

[0145] In summary, the statistical analysis results show that:

[0146] 1. The baseline BUT scores of the two groups before treatment were comparable;

[0147] 2. The experimental group was significantly better than the control group in improving tear film stability;

[0148] 3. The tear film stability of both groups of patients continued to improve with the extension of treatment time;

[0149] 4. The improvement effect of the experimental group was more significant, indicating that this treatment scheme has good clinical application value in improving tear film stability;

[0150] SIT score difference analysis:

[0151] Place the Schirmer test paper (5mm×35mm) with the tip folded inward into the conjunctival sac at the junction of the outer and middle thirds of the lower eyelid 1 / 35, and measure the length of the test paper soaked by tears within 5 minutes.

[0152] Table 5

[0153]

[0154] The SIT score data did not meet the normal distribution, and the Mann-Whitney U test was used for inter-group comparison, and the Wilcoxon signed rank test was used for intra-group comparison. The data analysis results showed:

[0155] 1. Comparison between groups

[0156] Before treatment, there was no significant difference in SIT scores between the control group and the experimental group (p>0.05), indicating that the baseline levels of the two groups were comparable. In the middle and after treatment, the SIT score of the experimental group was significantly higher than that of the control group (p<0.05), indicating that the experimental group was more effective in improving tear secretion.

[0157] 2. Intra-group comparison

[0158] (1) Control group:

[0159] The value during treatment was significantly greater than that before treatment (z=-4.794, p=0.000);

[0160] After treatment, it was significantly greater than before treatment (z=-4.797, p=0.000);

[0161] After treatment, it was significantly greater than during treatment (z=-3.033, p=0.002);

[0162] This indicates that the tear secretion function of patients in the control group was significantly improved over the treatment period, and showed a trend of continuous increase.

[0163] (2) Experimental group:

[0164] The value during treatment was significantly greater than that before treatment (z=-4.951, p=0.000);

[0165] After treatment, it was significantly greater than before treatment (z=-4.956, p=0.000);

[0166] After treatment, it was significantly greater than during treatment (z=-4.4163, p=0.000);

[0167] This indicates that the tear secretion of patients in the experimental group was significantly improved during the treatment, and the improvement was greater than that in the control group, indicating that the experimental regimen has a better therapeutic effect in promoting tear secretion.

[0168] In summary, the statistical analysis results show that:

[0169] 1. The baseline SIT scores of the two groups before treatment were comparable;

[0170] 2. The experimental group was significantly better than the control group in improving tear secretion function;

[0171] 3. The tear secretion of both groups of patients continued to improve with the extension of treatment time;

[0172] 4. The improvement effect of the experimental group was more significant, indicating that this treatment plan has clear clinical application value in increasing tear secretion;

[0173] Analysis of differences in meibomian gland scores:

[0174] The ocular surface comprehensive analyzer (keratograph5M) was used to evaluate the secretion of meibomian glands and the score of the missing area. Meibomian gland secretion score: ①0 points: normal meibum is clear and transparent; ②1 point: meibum is dirty; 2 points: meibum is dirty with debris (particles); ③3 points: meibum is thick and toothpaste-like. The sum of the upper and lower eyelid scores was recorded (0-6 points).

[0175] Table 6

[0176]

[0177] The meibomian gland score data did not meet the normal distribution, and the Mann-Whitney U test was used for inter-group comparison, and the Wilcoxon signed rank test was used for intra-group comparison. The data analysis results showed:

[0178] 1. Comparison between groups

[0179] Before treatment, there was no significant difference in the meibomian gland score between the control group and the experimental group (p>0.05), indicating that the baseline levels of the two groups were comparable. In the middle and after treatment, the meibomian gland score of the experimental group was significantly lower than that of the control group (p<0.05), indicating that the experimental group was more effective in improving the function of the meibomian glands.

[0180] 2. Intra-group comparison

[0181] (1) Control group:

[0182] The value during treatment was significantly smaller than that before treatment (z=-5.231, p=0.000);

[0183] After treatment, it was significantly smaller than before treatment (z=-5.066, p=0.000);

[0184] After treatment, it was significantly smaller than during treatment (z=-2.111, p=0.035);

[0185] This indicates that the degree of meibomian gland dysfunction in the control group improved over time, and the score gradually decreased, indicating that the meibomian gland function was restored to a certain extent.

[0186] (2) Experimental group:

[0187] The value during treatment was significantly smaller than that before treatment (z=-5.075, p=0.000);

[0188] After treatment, it was significantly smaller than before treatment (z=-5.336, p=0.000);

[0189] After treatment, it was significantly smaller than during treatment (z=-2.640, p=0.000);

[0190] This indicates that the meibomian gland function of the experimental group was significantly improved during the treatment, and the score decreased more than that of the control group, indicating that the experimental regimen has a better therapeutic effect in improving the meibomian gland function.

[0191] In summary, the statistical analysis results show that:

[0192] 1. The degree of meibomian gland dysfunction in the two groups before treatment was similar;

[0193] 2. The experimental group was significantly better than the control group in improving meibomian gland function;

[0194] 3. The meibomian gland function of both groups of patients continued to improve with the extension of treatment time;

[0195] 4. The improvement effect of the experimental group was more significant, indicating that this treatment regimen has a definite clinical efficacy in improving meibomian gland function.

[0196] Analysis of treatment effect:

[0197] Combined with the statistical results of the above indicators:

[0198]

[0199] in conclusion:

[0200] 1. The composition of the research subjects meets the epidemiological characteristics of dry eye;

[0201] 2. The sample sizes of the two groups were similar, the baseline levels were comparable, and they were well comparable;

[0202] 3. The experimental group showed obvious therapeutic advantages in all evaluation indicators;

[0203] 4. The total effective rate of the experimental group was significantly higher than that of the control group;

[0204] 5. The research results have reliable statistical significance;

[0205] These results confirm each other and jointly support that the experimental group treatment regimen has better clinical effects in improving the symptoms and signs of dry eye.

[0206] In summary, the fumigation composition provided by the embodiment of the present invention has a monarch drug, Poria cocos, which is good at removing dampness and has good effects on cold and dampness, damp heat, internal heat, etc. The ministerial drugs are Scutellaria baicalensis and Buddleja buddlejae. Scutellaria baicalensis can regulate the balance of yin and yang in the human body, remove damp heat in the lungs, liver and gallbladder, and large and small intestines, and can better improve the skin sores and swelling caused by damp heat stagnation. Buddleja buddlejae has the effects of clearing heat and nourishing the liver, improving eyesight and removing cataracts, and has a good effect on treating photophobia and tearing, red and swollen eyes. The two are combined with the monarch drug, and are supplemented with the effects of clearing heat, removing red cataracts, and removing dampness and heat. The adjuvant is Citrus aurantium, which has the power of drying dampness and resolving phlegm, and assists the monarch and ministerial drugs. The making drug is Licorice, which is flat in nature and harmonizes the Chu drug.

[0207] The raw materials are crushed and made into medicine bags. By adding water and boiling, the effective ingredients in the Chinese medicinal materials are dissolved in the water, and then the medicine is used for fumigation on the eyes, so that the heat and medicine can act on the patient's eyes together to nourish the eyes. The hot air can accelerate the penetration and absorption of the skin, so that the medicine can enter the capillaries and accelerate metabolism; steam can also stimulate the expansion of capillaries, accelerate blood circulation, and improve the vitality and regeneration of cell tissues. Through the Chinese medicine fumigation method, the local temperature is increased, the viscosity of the meibomian gland lipids is reduced, and it is liquefied for easy discharge, so as to achieve the purpose of improving the patient's condition.

[0208] The embodiments described above are part of the embodiments of the present invention, rather than all of the embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

Claims

1. A Chinese medicine fumigation composition for treating meibomian gland dysfunction, characterized in that: The following raw materials are included by weight: 10-20 parts of Poria cocos, 5-10 parts of Citrus aurantium, 10-15 parts of Scutellaria baicalensis, 10-15 parts of Buddleja buddleja, and 5-10 parts of Licorice.

2. The Chinese medicinal fumigation composition for treating meibomian gland dysfunction according to claim 1, characterized in that: The following raw materials are included by weight: 10 parts of Poria, 10 parts of Orange Peel, 10 parts of Scutellaria baicalensis, 10 parts of Buddleja Buddleja, and 10 parts of Licorice.

3. The Chinese medicinal fumigation composition for treating meibomian gland dysfunction according to claim 1, characterized in that: The following raw materials are included by weight: 20 parts of Poria cocos, 5 parts of Citrus aurantium, 15 parts of Scutellaria baicalensis, 15 parts of Buddleja mongholicus, and 5 parts of Licorice.

4. The Chinese medicinal fumigation composition for treating meibomian gland dysfunction according to claim 1, characterized in that: The following raw materials are included by weight: 15 parts of Poria, 8 parts of Orange Peel, 12 parts of Scutellaria baicalensis, 12 parts of Buddleja Buddleja, and 12 parts of Licorice.

5. A method for preparing a traditional Chinese medicine fumigation composition for treating meibomian gland dysfunction according to any one of claims 1 to 4, characterized in that: The following steps are involved: S1: Grind the raw materials separately, mix them evenly, and pack them into medicine bags; S2: placing the medicine bag in a container, adding water and boiling to obtain a Chinese medicine liquid, which is the fumigation composition.

6. The method for preparing the Chinese medicinal fumigation composition for treating meibomian gland dysfunction according to claim 5, characterized in that: In the step S1, the particle size of each raw material after crushing is 40-100 mesh.

7. The method for preparing the Chinese medicinal fumigation composition for treating meibomian gland dysfunction according to claim 6, characterized in that: In the step S1, each raw material is crushed to a particle size of 50 mesh.

8. The method for preparing the Chinese medicinal fumigation composition for treating meibomian gland dysfunction according to claim 6, characterized in that: In step S2, the boiling time is 10-20 minutes.

Images